Data processing: structural design – modeling – simulation – and em – Simulating nonelectrical device or system – Biological or biochemical
Reexamination Certificate
2011-08-02
2011-08-02
Noakes, Suzanne M. (Department: 1656)
Data processing: structural design, modeling, simulation, and em
Simulating nonelectrical device or system
Biological or biochemical
C702S019000
Reexamination Certificate
active
07991601
ABSTRACT:
An isolated GRP94 ligand binding domain polypeptide, a three-dimensional crystal structure of the same, and methods of using the same to design modulators of Hsp90 proteins.
REFERENCES:
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5834228 (1998-11-01), Becker et al.
patent: 5837251 (1998-11-01), Srivastava
patent: 5872011 (1999-02-01), Burley et al.
patent: 5961979 (1999-10-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6080730 (2000-06-01), Lemasters et al.
patent: 6106866 (2000-08-01), Ranney
patent: 6143299 (2000-11-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6180084 (2001-01-01), Ruoslahti et al.
patent: 7235649 (2007-06-01), Gewirth et al.
patent: 7439359 (2008-10-01), Chiosis et al.
patent: 7598355 (2009-10-01), Nicchitta et al.
patent: 7691969 (2010-04-01), Gewirth et al.
patent: 2001/0034042 (2001-10-01), Srivastava
patent: 2002/0006410 (2002-01-01), Lukacs et al.
patent: 2002/0160496 (2002-10-01), Gewirth et al.
patent: 2003/0054996 (2003-03-01), Nicchitta et al.
patent: 2003/0134787 (2003-07-01), Rothman et al.
patent: 2003/0215874 (2003-11-01), Gewirth et al.
patent: 2003/0216315 (2003-11-01), Nicchitta et al.
patent: 2008/0160636 (2008-07-01), Gewirth et al.
patent: 2002327804 (2009-01-01), None
patent: 2009/251191 (2010-01-01), None
patent: 2003216288 (2010-01-01), None
patent: 2429196 (2001-10-01), None
patent: 2460396 (2003-04-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO98/12208 (1998-03-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO99/29182 (1999-06-01), None
patent: WO99/42121 (1999-08-01), None
patent: WO00/20577 (2000-04-01), None
patent: WO01/052791 (2001-07-01), None
patent: WO01/72779 (2001-10-01), None
patent: WO03/028750 (2003-04-01), None
patent: WO03/029419 (2003-04-01), None
patent: WO03/068941 (2003-08-01), None
Argon et al., “GRP94, an ER chaperone with protein and peptide bindnig properties,” Cell & Developmental Biology, vol. 10, pp. 495-505 (1999).
Baker-LePain et al., “GRP94 (gp96) and GRP94 N-Terminal Geldanamycin Binding Domain Elicit Tissue Nonrestricted Tumor Suppression,”J. Exp. Med., 196(11): 1447-1459, Dec. 2, 2002.
Baker-LePain et al., “Suppression of Tumor Progression and Induction of Dendritic Cell Maturation Accompanies Secretion of Full Length and N-Terminal Regulatory Domain of GRP94(gp96),”Duke University Medical Center Publication, pp. 1-36.
Basu et al., “CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin,”Immunity, 14(3):303-313 (Mar. 2001) Abstract Only.
Basu et al., “Heat shock proteins: the fountainhead of innate and adaptive immune responses,”Cell Stress&Chaperones, 5(5):443-451 (2000).
Basu et al., “Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway,”International Immunology, 12(11):1539-1546 (Jul. 21, 2000).
Binder et al., “Adjuvanticity of alpha 2-macroglobulin, an independent ligand for the heat shock protein receptor CD91,”J. Immunol., 166(8):4968-4972 (Apr. 15, 2001) Abstract Only.
Binder et al., “CD91: a receptor for heat shock protein gp96,”Nat. Immunol., 1(2):100-101 (Aug. 2000) Abstract Only.
Breloer et al., “In Vivo and In Vitro Activation of T Cells After Administration of Ag-Negative Heat Shock Proteins,”J. Immunol., 162:3141-3147 (1999).
Cala et al. “GRP94 resides within cardiac sarcoplasmic reticulum vesicles and is phosphorylates by casein kinase II,” The Journal of Biological Chemistry. vol. 269, No. 8 pp. 5926-5931 (1994).
Communication pursuant to Article 94(3) EPC corresponding to European Patent Application No. 01 920 734.9-2401 dated Sep. 18, 2009.
Communication pursuant to Article 94(3) EPC corresponding to European Patent Application No. 03 739 824.5-2405 dated Jun. 27, 2008.
Communication pursuant to Article 94(3) EPC corresponding to European Patent Application No. 03 739 824.5-2405 dated Feb. 10, 2009.
Communication pursuant to Article 96(2) EPC corresponding to European Patent Application No. 02 763 818.8-1212 dated Oct. 25, 2007.
Communication pursuant to Article 96(2) EPC corresponding to European Patent Application No. 01 920734.9 dated Sep. 12, 2006.
Communication pursuant to Article 96(2) EPC corresponding to European Application No. 01 920 734.9-2401 dated Sep. 14, 2007.
Gilliland et al. Crystallization of biological molecules for X-ray diffraction studies. Current Opinion in Structure Biology 1996, 6, 595-603.
Grenert et al., “The Amino-terminal Domain of Heat Shock Protein 90 (hps90) That BindsGeldanamycin Is an ATPIADP Switch Domain That Regulates hsp90 Conformation,” The J. of Biological Chemistry, vol. 272(38), pp. 23843-23850 (Sep. 19, 1997).
International Peliminary Examination Report for corresponding PCT App No. PCT/US02/31207 dated Jul. 8, 2005.
International Search Report for International Patent Application No. PCT/US01/09512 dated Jul. 6, 2001.
International Search Report for International Patent Application No. PCT/US02/31014 dated Feb. 26, 2003.
International Search Report for PCT Application No. PCT/US03/04631 dated Oct. 3, 2005.
International Search Report or the Declaration corresponding to International Application No. PCT/US2002/31207 dated Mar. 25, 2005.
Jorgensen et al., “Polypeptide binding properties of the chaperone calreticulin,”Eur. J. Biochem., 267:2945-2954 (2000).
Kuge et al., “Use of a fusion protein to obtain crystals suitable for X-ray analysis: Crystallization of a GST-fused protein containing the DNA-binding domain of DNA replication-related element-binding factor, DREF,” Protein Science, vol. 6, pp. 1783-1786 (1997).
Letter from Japanese patent attorney summarizing Official Action in related Japanese Patent Application No. 2003532637 dated Aug. 12, 2008.
Li et al., “Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation,”EMBO J., 12(8):3143-3151 (Aug. 1993) Abstract Only.
Linderoth et al., “Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94),” The Journal of Biological Chemistry, vol. 275, No. 8, pp. 5472-5477 (2000).
Maki et al., “Human homologue of murine tumor rejection antigen grp96:5′-Regulatory and coding regions and relationship to stress-induced proteins,” PNAS, vol. 87 pp. 5658-5662 (1990).
NCBI Sequence Viewer 2.0 (2005) S.scrofa mRNA for gp96/GRP94 GRP94, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=2239252.
Notice of Acceptance corresponding to Australian Patent Application No. 2002327804 dated Sep. 11, 2008.
Notice of Acceptance corresponding to Australian Patent Application No. 2003216288 dated Sep. 24, 2009.
Notice of Allowance corresponding to U.S. Appl. No. 09/968,436 dated Feb. 20, 2007.
Notice of Allowance corresponding to U.S. Appl. No. 10/210,333 dated Apr. 21, 2009.
Notice of Allowance corresponding to U.S. Appl. No. 10/260,104 dated Apr. 9, 2009.
Notification of Transmittal of International Preliminary Examination Report for International Patent Application No. PCT/US02/31014 dated Sep. 28, 2004.
Notification of Transmittal of the International Preliminary Examination Report corresponding to International Application No. PCT/US01/09512 dated Oct. 18, 2001.
Official Action corresponding to Australian Patent Application No. 2002327804 dated Sep. 20, 2007.
Office Action corresponding to Australian Patent Application No. 2003216288 dated Aug. 28, 2008.
Office Action corresponding to European Patent Application No. 01 920734.9-2401 dated Sep. 11, 2008.
Office Action corresponding to European Patent Application No. 02 763 818.8-1212 dated Jun. 8, 2010.
Office Action corresponding to European Patent Applicat
Gewirth Daniel T.
Nicchitta Christopher V.
Duke University
Jenkins Wilson Taylor & Hunt, P.A.
Noakes Suzanne M.
LandOfFree
Isolated GRP94 ligand binding domain polypeptide and nucleic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated GRP94 ligand binding domain polypeptide and nucleic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated GRP94 ligand binding domain polypeptide and nucleic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2624893